Skip to content

Study · Animal study (in vivo) · rat · 2018

5 results

Limiting feeding to the active phase reduces blood pressure without the necessity of caloric reduction or fat mass loss.

Cote I, Toklu HZ, Green SM, Morgan D, Carter CS, Tümer N, Scarpace PJ

American journal of physiology. Regulatory, integrative and comparative physiology19 Jul 2018Cited by 16 (Europe PMC)

PMID30024775 (opens in a new tab)PMCIDPMC6230890 (opens in a new tab)DOI10.1152/ajpregu.00076.2018 (opens in a new tab)PepBankPUB-30024775
Source linkPubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In rats fed a high-fat diet, food intake was lower in both MTII groups than in saline controls.

    In plain wordsIn rats on a high-fat diet, MTII lowered food intake compared with saline.

    Peptide
    Melanotan II
    Outcome
    DecreaseFood intake
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Comparator
    Saline (Control)
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In study 2, food intake was significantly lower in both MTII groups relative to Control.
    1 context sentence
    Summary · context
    In study 2, rats fed a HFD were administered a long-acting α-MSH analog at either light onset [melanotan II (MTII) light] or dark onset (MTII dark) or saline (Control).
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In rats fed a high-fat diet, injection timing of MTII shifted food consumption between the light and dark phase; light-onset animals ate most calories in the active phase.

    In plain wordsIn rats, the time of the MTII injection changed when the rats ate; light-onset injection led to eating mostly in the active phase.

    Peptide
    Melanotan II
    Outcome
    MixedLight versus dark phase food consumption
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Comparator
    MTII dark onset injection
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    MTII light animals ate most of their calories during the active phase, similar to the TRF group.
    2 context sentences
    Summary · context
    Although timing of injection affected light versus dark phase food consumption
    Summary · context
    In study 2, rats fed a HFD were administered a long-acting α-MSH analog at either light onset [melanotan II (MTII) light] or dark onset (MTII dark) or saline (Control).
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats fed a high-fat diet, body weight did not differ between the MTII light and MTII dark groups.

    In plain wordsIn rats, body weight was the same whether MTII was given at light onset or dark onset.

    Peptide
    Melanotan II
    Outcome
    No significant changeBody weight, MTII light versus dark
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Comparator
    MTII dark onset injection
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    neither body weight nor fat mass differed between MTII groups.
    1 context sentence
    Summary · context
    In study 2, rats fed a HFD were administered a long-acting α-MSH analog at either light onset [melanotan II (MTII) light] or dark onset (MTII dark) or saline (Control).
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats fed a high-fat diet, fat mass did not differ between the MTII light and MTII dark groups.

    In plain wordsIn rats, fat mass was the same whether MTII was given at light onset or dark onset.

    Peptide
    Melanotan II
    Outcome
    No significant changeFat mass, MTII light versus dark
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Comparator
    MTII dark onset injection
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    neither body weight nor fat mass differed between MTII groups.
    1 context sentence
    Summary · context
    In study 2, rats fed a HFD were administered a long-acting α-MSH analog at either light onset [melanotan II (MTII) light] or dark onset (MTII dark) or saline (Control).
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In rats fed a high-fat diet and given MTII, rats that ate their calories in the active phase had lower mean arterial pressure; the abstract names no comparison group.

    In plain wordsIn rats on a high-fat diet given MTII, those eating mostly in their active phase had lower blood pressure; the comparison group is not named.

    Peptide
    Melanotan II
    Outcome
    DecreaseMean arterial pressure (MAP)
    Study

    ratn: not reported in source

    rats fed a high-fat diet
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated

    Source sentences

    Summary
    rats consuming their calories during the active phase displayed lower MAP.
    1 context sentence
    Summary · context
    In study 2, rats fed a HFD were administered a long-acting α-MSH analog at either light onset [melanotan II (MTII) light] or dark onset (MTII dark) or saline (Control).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.